Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Evaluation of Gynecologic Tumor Response: When and How?
      loading

      Chapter

      Evaluation of Gynecologic Tumor Response: When and How?

      DOI link for Evaluation of Gynecologic Tumor Response: When and How?

      Evaluation of Gynecologic Tumor Response: When and How? book

      Evaluation of Gynecologic Tumor Response: When and How?

      DOI link for Evaluation of Gynecologic Tumor Response: When and How?

      Evaluation of Gynecologic Tumor Response: When and How? book

      ByNoah A. Goldman, Carolyn D. Runowicz
      BookChemotherapy for Gynecological Neoplasms

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2004
      Imprint CRC Press
      Pages 14
      eBook ISBN 9780429120329
      Share
      Share

      ABSTRACT

      For many women with gynecologic malignancies, surgical intervention is only the beginning of treatment.Many patients require additional therapy. These patients need to be monitored for response to treatment, progression, or recurrence of disease. Monitoring a patient receiving chemotherapy or radiation may be difficult, as the currently available modalities do not have sufficient sensitivity or specificity to accurately predict persistent small-volume disease. How a patient is followed is often at the discretion of the treating physician and usually includes a combination of physical examination, serum tumor markers, imaging studies, and rarely, surgical reexploration. This chapter will discuss the role of tumor markers, imaging studies, and surgery in monitoring patients receiving chemotherapy for gynecologic cancers. Lacking prospective randomized trials, the recommendations put forth formonitoring these patients are largely based on expert opinion, nonrandomized studies, and clinical guidelines (1-3).

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited